Publications

Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD

Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.

New treatments for chronic urticaria

Filename 154. Kolkhir et al., New treatments chronic urt., AAAI 2020.pdf
Filesize 2 MB
Version r.154
Date added June 17, 2020
Downloaded 1 time
Category Reviews
Authors Kolkhir, P., Altrichter, S., Munoz, M., Hawro, T., and Maurer, M.
Citation Kolkhir, P., Altrichter, S., Munoz, M., Hawro, T., and Maurer, M.: New treatments for chronic urticaria. Ann. Allergy Asthma Immunol. 2020: 124; 2-12.
Corresponding authors Maurer, M.
DocNum r.154
DocType PDF
Edition; Page 124; 2-12
IF TBD (IF 2019: 4.97)
Publisher Ann. Allergy Asthma Immunol.
ReleaseDate 2020

Objective: Chronic urticaria (CU) is a common, heterogeneous, and debilitating disease. Antihistamines and omalizumab are the mainstay therapies of CU. Additional treatment options are needed. Here, we review the off and beyond label use of licensed drugs, novel treatments that are currently under development, and promising new targets.

Data Sources: MEDLINE was searched for recent reports of the successful use of treatments in CU and promising targets for the development of novel treatment options. We also searched ClinicalTrials.gov for recent and ongoing randomized clinical trials in CU.

Study Selections: Relevant articles were selected and reviewed.

Results: Omalizumab, the treatment of choice in patients with antihistamine-resistant chronic spontaneous urticaria (CSU), should be explored for use in chronic inducible urticaria in children younger than 12 years with CSU and at higher doses. The off-label use of dupilumab, reslizumab, mepolizumab, and benralizumab can be effective in CU. Ligelizumab and UB-221, 2 novel anti-IgE monoclonal antibodies, are in clinical trials for CU. Other promising drugs that are currently under development for CU are a chemoattractant receptor

(Last update: 02.2021)

Number of publications (original work and reviews) in peer-reviewed journals: 601
Number of original publications in peer-reviewed journals: 432
Number of reviews in peer-reviewed journals: 169
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: 3326,21
Cumulative IF for original publications in peer-reviewed journals: 2659,47
Cumulative IF for reviews in peer-reviewed journals: 666,74
Citations, Hirsch index: (view on Web of Science) 24104